BHST BioHarvest Sciences Inc: Enterprise Value to EBITDA Ratio
Intellectual property protection and strict regulatory standards create a formidable barrier for competitors attempting to replicate hydroponic synthesis methods. A cohesive team of plant cell biology experts ensures research stability. BioHarvest Sciences (BHST) revenues are based on the sale of bioactive components through the Bio-Plant system. This chart shows a market EV/EBITDA multiple of 0.00, visualizing the business value relative to its operating profit.
Comprehensive metric breakdowns and analytics for bioharvest.com (BHST)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity BioHarvest Sciences|BHST - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital BioHarvest Sciences Inc.|BHST - Company Debts|Debts to Book Capitalization BioHarvest Sciences Inc|BHST - Long-Term Debt Volume|Company Short-Term Debt BioHarvest Sciences|Quick Ratio bioharvest.com
- financial results and valuation multiples details:
BHST - Final Profit|Projected Future Earnings BioHarvest Sciences|BHST - P/E Multiple|Future Price to Earnings BioHarvest Sciences|BHST - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio BioHarvest Sciences Inc|BHST - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) BioHarvest Sciences|BHST - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bioharvest.com|BHST - Expected net earnings per share growth this year|Expected earnings per share growth for next year BioHarvest Sciences
Summary company analytics:BioHarvest BHST
BioHarvest Sciences (BHST) is scaling its VINIA platform and expanding into the US nutraceuticals market, which necessitates an assessment of capital intensity. The multiple compares the total enterprise value to operating profit before depreciation and amortization, determining the company's ability to service debt and taxes. An analysis of the company's EV/EBITDA value on this chart reveals stable cash flows during periods of turbulence. The decreasing volatility of this indicator confirms fundamental resilience during the transition to B2B contracts.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|MannKind Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Amphastar - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pacira Corp PCRX|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA theravance.com (TBPH)|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TECX|EV/EBITDA Multiple Tonix Pharmaceuticals Holding (TNXP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Business Value to Operating Income Before Depreciation EPRX|EXOZ: Enterprise Value to EBITDA Ratio|ORMP: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX: EV/EBITDA Multiple|Company Value to EBITDA MindWalk Therapeutics (HYFT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|cumberlandpharma.com (CPIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio QNTM (Quantum BioPharma)|Enterprise Value to Operating Income Before Depreciation Ratio FGEN|Telomir Pharma - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RANI|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Rallybio Corporation RLYB|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix Inc|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|Aptorum (APM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LYRA|IBO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD: Enterprise Value to Operating Income Before Depreciation|PainReform Limited - EV/EBITDA Multiple|Altamira Therapeutics (CYTO) - Enterprise Value to EBITDA Ratio|LIPO: EV/EBITDA Multiple|Company Value to EBITDA optinose.com (OPTN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group (PROC) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization QLI (Qilian International Corp)|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|Business Value to Operating Income Before Depreciation TFFP
